Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431015
Status:
COMPLETED
Last Update Posted:
2012-12-10
First Post:
2007-01-31
Brief Title:
Phase III Safety Study of IPI-504 in RelapsedRefractory Stage IIIb or Stage IV Non-small Cell Lung Cancer NSCLC
Sponsor:
Infinity Pharmaceuticals Inc
Organization:
Infinity Pharmaceuticals Inc
Study Overview
Official Title:
A Phase III Study to Investigate the Safety Tolerability and Potential Activity of IPI-504 in Relapsed and or Refractory Stage IIIb With Malignant Pleural or Pericardial Effusion or Stage IV NSCLC Patients
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer NSCLC The study will examine how IPI-504 is absorbed distributed metabolized and eliminated by the body The study will also evaluate the anti-tumor activity of IPI-504
Detailed Description:
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 Hsp90 an emerging and recently identified target for cancer therapy Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding function and viability of various client proteins Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival This clinical trial will study the effects of IPI-504 in a molecularly defined sub-group of patients who carry client proteins found in non-small cell lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None